8-K
filed June 5, 2026, 4:33 PM ET
ticker EWTX
CIK 0001710072
other
confidence high
sentiment neutral
materiality 0.10
Edgewise Therapeutics stockholders elect three directors, ratify auditor, approve say-on-pay at 2026 annual meeting
Edgewise Therapeutics, Inc.
- Laura Brege (87.3M for), Badreddin Edris (64.1M for), Jonathan Root (59.2M for) elected Class II directors.
- KPMG LLP ratified as independent auditor for FY2026 with 99.6M for, 1.1K against, 578K abstain.
- Say-on-pay advisory vote approved: 87.1M for, 3.5M against, 577K abstain.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.99
Edgewise Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 99,637,228 1,123 578,031
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
Edgewise Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2026-06-04 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 1: Election of three Class II Directors Name of Director For Withheld Laura Brege 87,300,827 3,822,867 Badreddin Edris, Ph.D. 64,082,681 27,041,013 Jonathan Root, M.D. 59,213,781 31,909,913
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.99
Edgewise Therapeutics, Inc. shareholders approved Advisory Vote on the Compensation of the Company's Named Executive Officers at the 2026-06-04 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers For Against Abstain 87,055,111 3,491,326 577,257
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.